Rice Hall James & Associates LLC Takes Position in Repligen Corporation $RGEN

Rice Hall James & Associates LLC purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 18,833 shares of the biotechnology company’s stock, valued at approximately $2,570,000.

A number of other institutional investors have also made changes to their positions in the stock. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the third quarter valued at about $29,000. Bayforest Capital Ltd bought a new position in Repligen during the fourth quarter worth about $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen during the fourth quarter worth about $33,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen in the 4th quarter valued at approximately $36,000. Finally, Farther Finance Advisors LLC lifted its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Down 1.7%

Repligen stock opened at $166.15 on Wednesday. The company has a market cap of $9.38 billion, a P/E ratio of 227.60, a price-to-earnings-growth ratio of 3.04 and a beta of 1.03. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The company has a fifty day simple moving average of $144.29 and a 200 day simple moving average of $131.18. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the previous year, the firm posted $0.26 EPS. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Royal Bank Of Canada began coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Finally, HSBC decreased their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.